Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials

被引:49
|
作者
Cohen, Stephanie C. [1 ]
Mulqueen, Jilian M. [2 ]
Ferracioli-Oda, Eduardo [3 ]
Stuckelman, Zachary D. [2 ]
Coughlin, Catherine G. [2 ]
Leckman, James F. [2 ,4 ]
Bloch, Michael H. [2 ,4 ]
机构
[1] Yale Univ, Sch Med, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT USA
[3] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil
[4] Yale Univ, New Haven, CT 06520 USA
基金
美国国家卫生研究院;
关键词
tics; psychostimulants; methylphenidate; amphetamine; meta-analysis; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; LA-TOURETTES DISEASE; ONCE-A-DAY; DOUBLE-BLIND; PHARMACOLOGICAL-TREATMENT; RELEASE METHYLPHENIDATE; STEREOTYPED BEHAVIOR; OROS METHYLPHENIDATE; STIMULANT TREATMENT;
D O I
10.1016/j.jaac.2015.06.011
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Objective: Clinical practice currently restricts the use of psychostimulant medications in children with tics or a family history of tics for fear that tics will develop or worsen as a side effect of treatment. Our goal was to conduct a meta-analysis to examine the risk of new onset or worsening of tics as an adverse event of psychostimulants in randomized, placebo-controlled trials. Method: We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled trials examining the efficacy of psychostimulant medications in the treatment of children with attention-deficit/hyperactivity disorder (ADHD). We used a fixed effects meta-analysis with risk ratio of new onset or worsening tics in children treated with psychostimulants compared to placebo. We used stratified subgroup analysis and meta-egression to examine the effects of stimulant type, dose, duration of treatment, recorder of side effect data, trial design, and mean age of participants on the measured risk of tics. Results: We identified 22 studies involving 2,385 children with ADHD for inclusion in our meta-analysis. New onset tics or worsening of tic symptoms were commonly reported in the psychostimulant (event rate = 5.7%, 95% CI = 3.7%-8.6%) and placebo groups (event rate = 6.5%, 95% CI = 4.4%-9.5%). The risk of new onset or worsening of tics associated with psychostimulant treatment was similar to that observed with placebo (risk ratio = 0.99, 95% CI = 0.78-1.27, z = 0.05, p = .962). Type of psychostirnulant, dose, duration of treatment, recorder, and participant age did not affect risk of new onset or worsening of tics. Crossover studies were associated with a significantly greater measured risk of tics with psychostimulant use compared to parallel group trials. Conclusion: Meta-analysis of controlled trials does not support an association between new onset or worsening of tics and psychostimulant use. Clinicians may want to consider rechallenging children who report new onset or worsening of tics with psychostimulant use, as these symptoms are much more likely to be coincidental rather than caused by psychostimulants.
引用
收藏
页码:728 / 736
页数:9
相关论文
共 50 条
  • [1] Antipsychotics for Cocaine or Psychostimulant Dependence: Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials
    Kishi, Taro
    Matsuda, Yuki
    Iwata, Nakao
    Correll, Christoph U.
    JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (12) : E1169 - U79
  • [2] Bupropion for adults with attention-deficit hyperactivity disorder: Meta-analysis of randomized, placebo-controlled trials
    Maneeton, Narong
    Maneeton, Benchalak
    Srisurapanont, Manit
    Martin, Stephen D.
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2011, 65 (07) : 611 - 617
  • [3] Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials
    Vukadinovic, Davor
    Scholz, Sean S.
    Messerli, Franz H.
    Weber, Michael A.
    Williams, Bryan
    Boehm, Michael
    Mahfoud, Felix
    JOURNAL OF HYPERTENSION, 2019, 37 (10) : 2093 - 2103
  • [4] Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials
    Meek, Patrick D.
    Evang, Samuel D.
    Tadrous, Mina
    Roux-Lirange, Dianne
    Triller, Darren M.
    Gumustop, Bora
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (01) : 7 - 18
  • [5] Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials
    Dykukha, Igor
    Malessa, Rolf
    Essner, Ute
    Ueberall, Michael A.
    PAIN MEDICINE, 2021, 22 (04) : 861 - 874
  • [6] Nocebo Effect in Meniere's Disease: A Meta-analysis of Placebo-controlled Randomized Controlled Trials
    Dimitriadis, Panagiotis A.
    Zis, Panagiotis
    OTOLOGY & NEUROTOLOGY, 2017, 38 (09) : 1370 - 1375
  • [7] Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials
    Yi, Xiao-yan
    Ni, Shi-fen
    Ghadami, Mohammad Rasoul
    Meng, Hua-qing
    Chen, Ming-yan
    Kuang, Li
    Zhang, Yu-qing
    Zhang, Li
    Zhou, Xin-yu
    SLEEP MEDICINE, 2018, 45 : 25 - 32
  • [8] Effectiveness of Valerian on insomnia: A meta-analysis of randomized placebo-controlled trials
    Isabel Fernandez-San-Martin, Ma
    Masa-Font, Roser
    Palacios-Soler, Laura
    Sancho-Gomez, Pilar
    Calbo-Caldentey, Cristina
    Flores-Mateo, Gemma
    SLEEP MEDICINE, 2010, 11 (06) : 505 - 511
  • [9] Efficacy of Antidepressants for Dysthymia: A Meta-Analysis of Placebo-Controlled Randomized Trials
    Levkovitz, Yeciel
    Tedeschini, Enrico
    Papakostas, George I.
    JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (04) : 509 - 514
  • [10] Oral isoflavone supplementation on endometrial thickness: a meta-analysis of randomized placebo-controlled trials
    Liu, Jie
    Yuan, Feixiang
    Gao, Jian
    Shan, Boer
    Ren, Yulan
    Wang, Huaying
    Gao, Ying
    ONCOTARGET, 2016, 7 (14) : 17369 - 17379